AKEEGA
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $165,850 | 267 | 223 |
| 2023 | $5,921 | 121 | 114 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $145,970 | 1 | 85.0% |
| Food and Beverage | $15,756 | 374 | 9.2% |
| Consulting Fee | $9,045 | 12 | 5.3% |
| Space rental or facility fees (teaching hospital only) | $1,000 | 1 | 0.6% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Hispanic/Latino and non-Hispanic BlAck patients treated with niRaparib and abiraterone acetate plus prednisone for Metastatic hOrmone sensitive prostate cancer with deleterious homologous recombinatioN repair alterations: a phase II, | Janssen Research & Development, LLC | $145,970 | 0 |
Top Doctors Receiving Payments for AKEEGA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Annmarie Clennan | — | Boca Raton, FL | $146,990 | 3 |
| , M.D | Urology | Omaha, NE | $825.46 | 2 |
| , M.D | Internal Medicine | Littleton, CO | $817.50 | 1 |
| , MD | Medical Oncology | Bolivar, MO | $817.50 | 1 |
| , MD | Urology | Tallahassee, FL | $817.50 | 1 |
| , MD | Hematology & Oncology | Pittsburgh, PA | $817.50 | 1 |
| , MD | Urology | Merrillville, IN | $817.50 | 1 |
| , M.D./PH.D | Urology | Chicago, IL | $817.50 | 1 |
| , MD | Hematology & Oncology | Ypsilanti, MI | $817.50 | 1 |
| , M.D | Hematology & Oncology | Dillon, CO | $817.50 | 1 |
| , FNP-C | Family | Detroit, MI | $562.50 | 1 |
| , APRN, NP-C | Nurse Practitioner | Jeffersonville, IN | $562.50 | 1 |
| , PA | Physician Assistant | Santa Monica, CA | $562.50 | 1 |
| , N.P.-C | Nurse Practitioner | San Diego, CA | $158.79 | 2 |
| , NP | Nurse Practitioner | San Diego, CA | $158.79 | 2 |
| , NP | Urology | Los Angeles, CA | $149.93 | 1 |
| , MD | Internal Medicine | Los Angeles, CA | $146.66 | 1 |
| , MD | Surgery | Houston, TX | $146.57 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Houston, TX | $146.57 | 1 |
| , MD | Urology | Houston, TX | $146.57 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Houston, TX | $146.57 | 1 |
| , MD | Internal Medicine | Houston, TX | $146.57 | 1 |
| , MD | Urology | Houston, TX | $146.57 | 1 |
| , M.D | Urology | Houston, TX | $146.57 | 1 |
| , M.D | Urology | Houston, TX | $146.57 | 1 |
Manufacturing Companies
- Janssen Research & Development, LLC $146,004
- Janssen Scientific Affairs, LLC $14,426
- Janssen Biotech, Inc. $8,926
- Johnson & Johnson Health Care Systems Inc. $2,197
- Janssen Global Services, LLC $131.57
- Janssen Pharmaceuticals, Inc $86.86
Product Information
- Type Drug
- Total Payments $171,771
- Total Doctors 332
- Transactions 388
About AKEEGA
AKEEGA is a drug associated with $171,771 in payments to 332 healthcare providers, recorded across 388 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Research & Development, LLC.
Payment data is available from 2023 to 2024. In 2024, $165,850 was paid across 267 transactions to 223 doctors.
The most common payment nature for AKEEGA is "Unspecified" ($145,970, 85.0% of total).
AKEEGA is associated with 1 research study, including "Hispanic/Latino and non-Hispanic BlAck patients treated with niRaparib and abiraterone acetate plus prednisone for Metastatic hOrmone sensitive prostate cancer with deleterious homologous recombinatioN repair alterations: a phase II," ($145,970).